Drug Type Small molecule drug |
Synonyms MDC-405+, SAL-0101 |
Target |
Action inhibitors |
Mechanism Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC70H86ClFN6O22 |
InChIKeyZMDKGABGPBZBQT-QUFZNYFDSA-N |
CAS Registry2133857-12-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced breast cancer | Phase 1 | China | 17 Sep 2021 | |
Colorectal Cancer | Phase 1 | China | 17 Sep 2021 | |
Esophageal Carcinoma | Phase 1 | China | 17 Sep 2021 | |
Melanoma | Phase 1 | China | 17 Sep 2021 | |
Non-Small Cell Lung Cancer | Phase 1 | China | 17 Sep 2021 | |
Ovarian Cancer | Phase 1 | China | 17 Sep 2021 | |
Pancreatic Cancer | Phase 1 | China | 17 Sep 2021 | |
Prostatic Cancer | Phase 1 | China | 17 Sep 2021 | |
Squamous Cell Carcinoma of Head and Neck | Phase 1 | China | 17 Sep 2021 | |
Stomach Cancer | Phase 1 | China | 17 Sep 2021 |